Permanent I-125 seed implant brachytherapy for prostate carcinoma

Atsunori Yorozu, K. Toya, T. Ohashi, M. Okada, T. Kasamatsu, R. Ito, T. Monma, S. Saito

Research output: Contribution to journalArticle

Abstract

Permanent prostate brachytherapy has been increasingly used as a highly curative treatment for clinically localized prostate cancer. Many brachytherapy studies have reported favorable long-term biochemical outcomes. with a minimal morbidity that compares with surgery or external beam radiotherapy. So I-125 seed implant must be a best treatment option for a low risk group. There are some contraindications or limitation for brachytherapy. There is a learning curve as well. Combined treatment with external beam or hormone treatment may be necessary for intermediate or high risk groups. It is possible that high-quality brachytherapy may have more favorable results.

Original languageEnglish
Pages (from-to)619-624
Number of pages6
JournalJapanese Journal of Clinical Radiology
Volume50
Issue number5
Publication statusPublished - 2005 Jun 13
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Permanent I-125 seed implant brachytherapy for prostate carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Yorozu, A., Toya, K., Ohashi, T., Okada, M., Kasamatsu, T., Ito, R., Monma, T., & Saito, S. (2005). Permanent I-125 seed implant brachytherapy for prostate carcinoma. Japanese Journal of Clinical Radiology, 50(5), 619-624.